(2008). (page number not for citation purposes)Shiota G: CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. Biochem Biophys Res Commun
A and Zupi G: Lonidamine induces apoptosis in drugresistant cells independently of the p53 gene. JC l i nI n v e s t1996,
(2001). A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res
(2001). Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene
and Cavenee W: WHO classification of tumours. Pathology and genetics: tumours of the nervous system
(2003). Andrieu JM and Delattre JY: Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme.
(2005). Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene
(2000). Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol
(1999). Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther
(1999). Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells.
(2004). Betulinic acid: a promising anticancer candidate. IDrugs
Bigner DD and Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. JC l i nO n c o l2004,
(1988). Caputo A and Floridi A: Effect of lonidamine on human malignant gliomas: biochemical studies.
(2005). CD437, a synthetic retinoid, induces apoptosis in human respiratory epithelial cells via caspase-independent mitochondrial and caspase-8-dependent pathways both up-regulated by JNK signaling pathway. Exp Cell Res
(1999). Characterization of a silencer element and purification of a silencer protein that negatively regulates the human adenine nucleotide translocator 2 promoter. JB i o lC h e m
(2002). Classical and novel retinoids: their targets in cancer therapy. Leukemia
(2004). Debatin KM and Herold-Mende C: Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir (Wien)
(2006). Di L i s aFa n dF o r t eM A :The mitochondrial permeability transition from in vitro artifact to disease target.
(1991). Differential regulation of expression of the multiple ADP/ATP translocase genes in human cells.
(1981). Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res
(2006). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA
(1998). Expression of human ANT2 gene in highly proliferative cells: GRBOX, a new transcriptional element, is involved in the regulation of glycolytic ATP import into mitochondria. JM o l Biol
(2002). GambacortiPasserini C and Formelli F: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett
(2007). Genetic pathways to primary and secondary glioblastoma.
(2005). Identification of protein modulation by the synthetic retinoid CD437 in lung carcinoma cells using high throughput immunoblotting.
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
(1994). Interferon gamma up-regulates alpha 2 macroglobulin expression in human astrocytoma cells. JN e u r o i m -munol
(2004). Jeremias I and Debatin KM: Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene
(2007). Live-cell assay for detection of apoptosis by dual-laser flow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nat Protoc
Majumdar AP and Reichert U: Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. JB i o lC h e m2003,
(1998). Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.
(2006). Mitochondria: a target for cancer therapy.
(2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev
(2000). Mitochondrion as a novel target of anticancer chemotherapy. JN a t l Cancer Inst
(2007). New molecular targets in malignant gliomas. Curr Opin Neurol
(2006). of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. JC l i nO n c o l1999,
(2001). Perzelova A and Tardy M: Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation.
(2005). PIGA (N,N-Di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells. Chembiochem
(2007). Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
(1999). Soddu S and Zupi G: Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther
(2007). Soprano DR and Soprano KJ: GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells. JC e l l Physiol
(1995). The mitochondrial permeability transition. Biochim Biophys Acta
(2006). The permeability transition pore complex in cancer cell death. Oncogene
(2003). Tinel N and Casellas P: The peripheral benzodiazepine receptor: a promising therapeutic drug target. Curr Med Chem
(2006). Visualization of mitochondrial membrane potential and reactive oxygen species via double staining. Neurosci Lett